sie in pre open!!!!!!!!, page-4

1/4 report out Stead steady it moves forward,

Receipts looking better this 1/4,but still burning cash each month

________________
PART
ASX Announcement and Media Release
30 July 2004
SciGen Limited
Strong growth in cash receipts for FY2004.
SciGen Limited (�gSciGen�h or the �gCompany�h) today released its Appendix 4C (cash flow report)
for the June 2004 Quarter and the full financial year ended 30 June 2004.
Cash receipts from customers for the full year ended 30 June 2004 were more than double that
of the previous financial year. This strong growth in cash receipts in the past year is
characteristic of SciGen�fs growth path over the past 20 months since joining the Official List of
the ASX.
Full year cash receipts from customers were S$5.4M (A$4.4M) comparing very favourably to the
FY2003 cash receipts of S$2.0M (A$2.0M).
For the quarter ended 30 June 2004, cash receipts from customers were S$1.7M (A$1.4M) -
down slightly on the March Quarter result due to timing of orders from larger customers and the
previously announced temporary interruption to supply of Sci-B-Vac.
Cash held at the end of the June Quarter was S$9.6M (A$8.1M).
Average monthly net cash burn for FY2004 (excluding one-off license fee payments and noncash
flow exchange rate variances) was S$395K (A$322K).
As instituted in the March 2004 Quarter, the Appendix 4C is presented in both Singapore Dollars
and Australian Dollars as the Company moves towards using Singapore Dollars as its principal
reporting currency. This will occur by the end of the September Quarter 2004. This will remove
the non-cash flow exchange rate variances which can cause confusion in interpreting results.
Mark Compton, Managing Director of SciGen said �gContinuing sales growth, particularly in
SciTropinTM (recombinant human growth hormone) sales, is very encouraging, as is the
continuing achievement of health registrations for our products and subsequent sales of those
products in various territories.�h
�gMost notable is the recent health registration of our recombinant human insulin (SciLinTM) in
India. We are now working on the final preparations to commence sales in that large and
growing market through our Indian partners Shreya Life Sciences and Ranbaxy Laboratories�h
�gOur established strategic partnerships in India, China and in other territories where the
company has commercialisation agreements in place, currently comprehend minimum order
projections (binding and non-binding) in the order of US$33.5M. The timing of this revenue is
subject to meeting the requirements and timelines of regulatory authorities, combined with their
internal assessment processes to achieve health registration of our products.�h Mr Compton said.